Pioneering the Future of Brain Health
We started NeuroView because we saw patients struggling — and we knew technology could do better. After 30 years of treating epilepsy, our founders built what patients and doctors have been waiting for.
Our Mission
We believe every person with epilepsy deserves to understand their brain. Our mission is to replace guesswork with certainty — giving patients real answers, doctors real data, and families real peace of mind.
The Ally 100 is the first long-term, minimally invasive brain monitor. It catches seizures your diary misses, identifies patterns your doctor needs, and gives you a continuous window into your brain health.
When seizures go undetected, the consequences are real: higher risk of injury, reduced quality of life, and treatments that don't work because they're based on incomplete information. We're here to change that.
Data-Driven Decision Making
Your brain generates data every second. We use AI and machine learning to turn that data into answers — personalized insights that help your doctor make better decisions, faster.
Better outcomes. Faster treatment optimization. Fewer ER visits. Lower costs. This is what happens when your care team has the full picture — not just a snapshot.
Key Milestones
Dr. Kuzniecky receives AES Research Recognition Award for Clinical Science
Publication of algorithm study and validation study of Subgaleal EEG
Successful completion of canine trial at University of Colorado
NIH Blueprint MedTech Seedling Grant awarded
Epilepsy Foundation Shark Tank Award; NEJM publication on digital tech for epilepsy
Scott Verner appointed CEO; Growth round initiated
Advancing toward FDA clinical trials within 18 months
What We've Accomplished
Explore the Ally 100
Learn how our minimally invasive EEG implant provides 1,095 days of continuous brain monitoring data.
View TechnologyMeet Our Team
World-renowned epileptologists from NYU and Northwell Health, bioelectronics researchers, and medtech executives.
View TeamGet in Touch
Whether you're a patient, physician, or investor — we'd love to hear from you about continuous brain monitoring.
Contact Us